Traders should monitor for any FDA communications, potential advisory committee meetings, or clinical updates ahead of the September 19, 2026 PDUFA date. Positive momentum in RARE stock is likely to continue unless new regulatory concerns emerge. Consider positioning for event-driven volatility as the action date approaches.
RARE drugs
RARE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $22.45entry
- T+1 · 8mo ago +1.87%α +1.40% · $22.87
- T+5 · 7mo ago +3.79%α +0.17% · $23.30
- T+20 · 7mo ago +9.98%α +0.10% · $24.69
- T+60 · 5mo ago +48.73%α +34.57% · $33.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ultragenyx Pharmaceutical Inc. announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA), with a PDUFA action date of September 19, 2026. This marks a key regulatory milestone for a potential first-in-class therapy for a rare and severe pediatric neurodegenerative disease.
Key Facts
- FDA accepted resubmitted BLA for UX111 (rebisufligene etisparvovec) for accelerated approval
- Indication: Sanfilippo syndrome Type A (MPS IIIA), a rare pediatric neurodegenerative disorder
- PDUFA action date set for September 19, 2026
- Therapy is an AAV9 gene therapy, representing a potential one-time treatment
- Filing follows prior rejection, indicating successful resolution of prior FDA concerns
Financial Impact
Potential blockbuster revenue if approved; UX111 could achieve peak sales estimates in the hundreds of millions to over $1 billion annually, given the high unmet need and lack of approved therapies for MPS IIIA
Risk Factors
- FDA may ultimately deny approval despite acceptance for review
- Potential requirement for post-marketing studies or restrictive labeling
- Manufacturing or safety issues could delay or block approval
- Competition from other gene therapies or emerging modalities in rare neurogenetic diseases
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-139084 |
| Document: 0001193125-26-139084-index.html | 0001193125-26-139084 |
| Document: 0001193125-26-139084.txt | 0001193125-26-139084 |
Track record
22 reports on RARE
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +16.16% at T+20 after the Mar 2, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers